ESC Heart Failure:非侵入性方法测量慢性心力衰竭患者身体成分结果比较

2021-07-04 MedSci原创 MedSci原创

恶病质(cachexia)亦称恶液质。表现为极度消瘦,皮包骨头,形如骷髅,贫血,无力,完全卧床,生活不能自理,极度痛苦,全身衰竭等综合征,在慢性心力衰竭 (CHF)患者 中很常见,

恶病质(cachexia)亦称恶液质。表现为极度消瘦,皮包骨头,形如骷髅,贫血,无力,完全卧床,生活不能自理,极度痛苦,全身衰竭等综合征,在慢性心力衰竭 (CHF)患者 中很常见,患病率为5%15%然而,由于细胞外液的变化,检测CHF患者的恶病质尤其具有挑战性。

pixabay

近日,发表在ESC Heart Failure杂志的一项研究通过双能 X 射线吸收仪 (DEXA) 和多频生物电阻抗分析 (BIA) 设备测量了身体成分。研究人员评估了平均年龄为70岁的120CHF患者的身体成分。植入心脏除颤器或起搏器的患者被排除在外,因为此类患者禁用生物电阻抗测量。不能平躺或超过 DEXA 机器 150 公斤体重限制的患者也被排除在外。所有患者在同一天进行两次身体成分评估,其中还包括完整的血管临床病史和检查、血液检查、心电图和超声心动图等。

结果显示,BIA测量的平均脂肪量 (FM) 27.2 (11.7) kg,而DEXA测量的FM32.3 (12.2) kgBIA 的平均 (SD) 瘦体重 (LM) 56.6 (10.9) kg,而DEXA 51.1 (9.9) kgBIA测量的平均骨量(BM)为3.00.5kg,而DEXA 2.80.6kgDEXABIA身体成分测量与其他身体尺寸测量(身体质量指数、臀围和腰围)都有很好的相关性。

BIA DEXA 测量的身体成分

该研究结果证实并扩展了其他科学家将DEXA BIA 进行比较的结果。用于评估身体成分的设备不可互换。尽管 DEXA 是一种辐射源,但它仍是人体成分分析的参考方法。BIA 设备可以在门诊就诊的同时快速评估身体成分,可能更方便,但需要在恶病质研究中进一步验证。

总之,DEXA BIA两种技术在 FMLM BM 的测量上存在差异,不应互换使用。

原始出处

Parin Shah.et al.A comparison of non-invasive methods of measuring body composition in patients with heart failure: a report from SICA-HF.ESC Heart Failure https://doi.org/10.1002/ehf2.13402

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034705, encodeId=39342034e0534, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat May 14 03:07:42 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906213, encodeId=1a5e19062134e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Apr 25 04:07:42 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028824, encodeId=54f72028824d7, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Jul 24 03:07:42 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251818, encodeId=1caf1251818c2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357731, encodeId=b03b135e73100, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537421, encodeId=dddc153e421f6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563480, encodeId=f1271563480f8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2034705, encodeId=39342034e0534, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat May 14 03:07:42 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906213, encodeId=1a5e19062134e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Apr 25 04:07:42 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028824, encodeId=54f72028824d7, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Jul 24 03:07:42 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251818, encodeId=1caf1251818c2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357731, encodeId=b03b135e73100, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537421, encodeId=dddc153e421f6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563480, encodeId=f1271563480f8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
    2022-04-25 amy0550
  3. [GetPortalCommentsPageByObjectIdResponse(id=2034705, encodeId=39342034e0534, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat May 14 03:07:42 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906213, encodeId=1a5e19062134e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Apr 25 04:07:42 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028824, encodeId=54f72028824d7, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Jul 24 03:07:42 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251818, encodeId=1caf1251818c2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357731, encodeId=b03b135e73100, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537421, encodeId=dddc153e421f6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563480, encodeId=f1271563480f8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2034705, encodeId=39342034e0534, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat May 14 03:07:42 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906213, encodeId=1a5e19062134e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Apr 25 04:07:42 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028824, encodeId=54f72028824d7, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Jul 24 03:07:42 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251818, encodeId=1caf1251818c2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357731, encodeId=b03b135e73100, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537421, encodeId=dddc153e421f6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563480, encodeId=f1271563480f8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2034705, encodeId=39342034e0534, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat May 14 03:07:42 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906213, encodeId=1a5e19062134e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Apr 25 04:07:42 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028824, encodeId=54f72028824d7, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Jul 24 03:07:42 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251818, encodeId=1caf1251818c2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357731, encodeId=b03b135e73100, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537421, encodeId=dddc153e421f6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563480, encodeId=f1271563480f8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
    2021-07-06 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=2034705, encodeId=39342034e0534, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat May 14 03:07:42 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906213, encodeId=1a5e19062134e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Apr 25 04:07:42 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028824, encodeId=54f72028824d7, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Jul 24 03:07:42 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251818, encodeId=1caf1251818c2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357731, encodeId=b03b135e73100, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537421, encodeId=dddc153e421f6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563480, encodeId=f1271563480f8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2034705, encodeId=39342034e0534, content=<a href='/topic/show?id=cf91992e053' target=_blank style='color:#2F92EE;'>#非侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99270, encryptionId=cf91992e053, topicName=非侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Sat May 14 03:07:42 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906213, encodeId=1a5e19062134e, content=<a href='/topic/show?id=d7d3e2249e' target=_blank style='color:#2F92EE;'>#failure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7224, encryptionId=d7d3e2249e, topicName=failure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Mon Apr 25 04:07:42 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028824, encodeId=54f72028824d7, content=<a href='/topic/show?id=b1e1269e5c6' target=_blank style='color:#2F92EE;'>#侵入性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26975, encryptionId=b1e1269e5c6, topicName=侵入性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Jul 24 03:07:42 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251818, encodeId=1caf1251818c2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357731, encodeId=b03b135e73100, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537421, encodeId=dddc153e421f6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563480, encodeId=f1271563480f8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Jul 06 07:07:42 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
    2021-07-06 slcumt

相关资讯

慢性心力衰竭基层诊疗指南(实践版·2019)

心力衰竭(心衰)是一种临床综合征,定义为由于任何心脏结构或功能异常导致心室充盈或射血能力受损的一组复杂临床综合征。其主要临床表现为呼吸困难和乏力(活动耐量受限),以及液体潴留(肺淤血和外周水肿)。

JACC:个性化的营养支持可明显降低慢性心衰患者的死亡和主要心血管事件风险

对于具有高营养不良风险的因慢性心力衰竭住院的患者,个性化的营养支持可相比标志医院饮食降低其死亡和主要心血管事件风险

Eur J Heart Fail:社区慢性心力衰竭患者的生存情况

由此可见,这些结果可以为健康政策和个体患者的高级护理计划提供信息。尽管生存率稳步提高,但与慢性心力衰竭相关的死亡率仍然很高。通过更多的循证治疗,仍有很大程度改善预后的空间。建议进一步研究探索阻碍和促进治疗的因素。

Nat Commun:IRF1-PGC1α通路对4型心肾综合征的贡献

冠心病(CVD)是慢性肾病(CKD)最常见并发症,且是CKD患者的主要死亡原因(超过50%)。CKD可能导致心脏病理的改变,包括左心室肥大(LVH)、心脏舒张功能障碍和/或心血管事件风险的提高,这种情

Eur Heart J Cardiovasc Pharmacother:慢性心力衰竭患者的肾脏保护:关注沙库巴曲/缬沙坦

慢性肾脏病(CKD)在慢性心力衰竭(CHF)患者中非常普遍,并且对全球和心血管(CV)死亡率造成相当不利的预后负担[1]。关键的CHF试验数据显示CKD的患病率在32%到50%之间,在大约30%的心力

慢性心力衰竭基层诊疗指南(2019年)

简要介绍:心力衰竭(心衰)是一种临床综合征,定义为由于任何心脏结构或功能异常导致心室充盈或射血能力受损的一组复杂临床综合征。其主要临床表现为呼吸困难和乏力(活动耐量受限)以及液体潴留(肺淤血和外周水肿)。 该指南从基层医疗卫生机构的实际工作出发,在心力衰竭早期识别与诊断、转诊和社区管理、患者自我管理和家庭管理方面给出了明确的指导。